Colon Cancer Clinical Trial
Official title:
BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
Verified date | August 2013 |
Source | Braintree Laboratories |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a randomized, parallel, multi-center, single-blind study, comparing BLI850 to an FDA approved bowel preparation in adult subjects undergoing colonoscopy.
Status | Completed |
Enrollment | 394 |
Est. completion date | |
Est. primary completion date | November 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Male or female outpatients who are undergoing colonoscopy for a routinely accepted indication, including: - Evaluation of barium enema results - GI bleeding - Anemia of unknown etiology - Neoplastic disease surveillance - Abnormal Endosonography - Inflammatory bowel disease - Unknown diarrhea or constipation etiology - Polypectomy - Laser therapy - Routine screening 2. At least 18 years of age. 3. Otherwise in good health, as determined by physical exam and medical history. 4. If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, abstinent, or vasectomized spouse). 5. Negative urine pregnancy test at screening, if applicable. 6. In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study. Exclusion Criteria: 1. Subjects with known or suspected ileus, severe ulcerative colitis, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. 2. Subjects with impaired consciousness that predisposes them to pulmonary aspiration. 3. Subjects who are undergoing colonoscopy for foreign body removal or decompression. 4. Subjects with clinically significant electrolyte abnormalities based on Visit 1 laboratory results. 5. Subjects who had previous significant gastrointestinal surgeries (e.g. colostomy, colectomy, gastric bypass). 6. Subjects who are pregnant or lactating, or intending to become pregnant during the study. 7. Subjects of childbearing potential who refuse a pregnancy test. 8. Subjects who are allergic to any preparation components 9. Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures. 10. Subjects who have participated in an investigational surgical, drug, or device study within the past 30 days. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Southeastern Clinical Research | Chattanooga | Tennessee |
United States | Long Island GI Research Group | Great Neck | New York |
United States | Carolina Digestive Health Associates | Harrisburg | North Carolina |
United States | Jupiter Research | Jupiter | Florida |
United States | Regional Gastroenterology Associates of Lancaster | Lancaster | Pennsylvania |
United States | Maryland Digestive Disease Research | Laurel | Maryland |
United States | Miami Research Associates | Miami | Florida |
United States | University of South Alabama | Mobile | Alabama |
United States | Delta Research Partners | Monroe | Louisiana |
United States | United Medical Research | New Smyrna Beach | Florida |
United States | Wake Research Associates | Raleigh | North Carolina |
United States | Atlanta Gastroenterology Associates | Roswell | Georgia |
Lead Sponsor | Collaborator |
---|---|
Braintree Laboratories |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy - Preparation Quality Using a 4 Point Scale | Percentage of patients with a successful preparation (cleaning rated as "Good" or "Excellent" | 2-day | No |
Secondary | Serum Chemistry Results (mg/dL) | Change from Baseline | 2 days | Yes |
Secondary | Hematology Results (%) | Change from Baseline | 2 days | Yes |
Secondary | Serum Chemistry Results (U/L) | Change from Baseline | 2 days | Yes |
Secondary | Serum Chemistry Results (mEq/L) | Change from Baseline | 2 days | Yes |
Secondary | Serum Chemistry Results (g/dL) | Change from Baseline | 2 days | Yes |
Secondary | Serum Chemistry Results (GFR) | Change from Baseline | 2 days | Yes |
Secondary | Hematology Results (1000/MCL) | Change from Baseline | 2 days | Yes |
Secondary | Hematology Results - Hemoglobin | Change from Baseline | 2 days | Yes |
Secondary | Hematology Results - Red Blood Cells | Change from Baseline | 2 days | Yes |
Secondary | Serum Chemistry Results (Osmolality) | Change from Baseline | 2 days | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT03457454 -
Reducing Rural Colon Cancer Disparities
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03390907 -
Hybrid APC Assisted EMR for Large Colon Polyps
|
N/A | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT04079478 -
The AID Study: Artificial Intelligence for Colorectal Adenoma Detection
|
||
Active, not recruiting |
NCT04057274 -
Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth
|
N/A | |
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05147545 -
Impact of Exercise and Hyperlipidic Meal on Free Circulating DNA in Patients With Metastatic Colonic Cancer and Healthy Subjects
|
N/A | |
Recruiting |
NCT05026268 -
The Laparoscopic Right Colectomy With Intracoroporeal Anastomosis
|
N/A | |
Not yet recruiting |
NCT03277235 -
Effect of a Resilience Model-Based Care Plan in Newly Diagnosed Colorectal Cancer Patients
|
N/A | |
Active, not recruiting |
NCT02959541 -
PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
|
N/A | |
Active, not recruiting |
NCT02730702 -
Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure
|
||
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A | |
Recruiting |
NCT02577627 -
Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC
|
N/A | |
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Recruiting |
NCT02526836 -
Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer
|
Phase 2/Phase 3 |